Viking Therapeutics Recovers After CPI, Returns to $80 Level, Eyes $100 Within Year

Viking Therapeutics (VKTX) has seen a significant recovery following the release of the Consumer Price Index (CPI). The company has attracted substantial interest from major biotech funds, including Avoro Capital and Perceptive Advisors, both of which have recently added VKTX to their portfolios. Avoro Capital has a history of successful buyouts, including recent acquisitions of IMGN, MRTX, and KRTX. Additionally, Merck's management made a positive comment about VKTX's assets, further boosting investor confidence. The stock has returned to the $80 level, with some investors anticipating it could reach $100 within the year. VKTX is noted for its high short interest, which is seen as a catalyst for further gains. Long-term investors have held through periods of volatility, and the stock's performance is now reflecting their patience.